Atlas Architect

Decision Instrument

Decision Output

Recommendation / Next Best Action

Capture recommended architecture, rationale, alternatives not selected, and highest-priority experiments in an export-style decision brief.

Recommended architecture

Proceed with focused redesign constraints

Engineered AAV systemic CNS delivery

Moderate-high confidence (0.72) with translation and immunity as dominant uncertainty drivers.

Why selected

  • Best combined score for CNS coverage, durability fit, and strategic scalability.
  • Maintains path to clinically realistic administration workflow.
  • Engineering levers directly map to highest-value bottlenecks.

Why alternatives were not selected

  • Intrathecal/local AAV: strong near-term feasibility but inadequate broad tissue coverage.
  • LNP transient editor: repeat-dose upside offset by CNS penetration and durability gaps.

Next experiments

Priority 1

NHP biodistribution benchmark with CNS:liver quantitative endpoint.

Priority 2

Human sera panel for neutralizing antibody escape profiling.

Priority 3

Innate immune signature study at projected clinical dose band.

Priority 4

Manufacturing mini-pilot with capsid variant panel and full QC readout.

One-page export card

Program status: Proceed with constrained redesign; evaluate kill criteria after first translational package.